Navigation Links
Ondine Biopharma Announces Second Quarter 2008 Financial Results
Date:8/14/2008

VANCOUVER, Aug. 14 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (the "Company" or "Ondine", TSX: OBP; AIM: OBP) a medical technology company developing photodisinfection based products, today announced its financial results for the second quarter ended June 30, 2008.

"During the past quarter we made significant regulatory and clinical progress with our photodisinfection technology and we are leveraging our successes to advance discussions with prospective strategic partners," stated Carolyn Cross, Ondine's President & CEO, "We also took steps to build on our technology as we see the opportunity to address many unmet medical needs with our photodisinfection platform. Accordingly, having validated Periowave (TM) in the Canadian dental market, we are refocusing our resources on new product development and obtaining appropriate strategic partners for the commercialization and co-development of our photodisinfection-based product pipeline."

2008 Second Quarter Results and Recent Developments

FINANCIAL RESULTS

For the quarter ended June 30, 2008 (the "Second Quarter of 2008"), the Company recorded a loss of $2.43 million or $0.04 per common share compared with a loss of $3.79 million or $0.07 per common share during the quarter ended June 30, 2007 (the "Second Quarter of 2007"). For the six months ended June 30, 2008 (the "First Half of 2008"), the Company recorded a loss of $4.9 million or $0.08 per common share compared with a loss of $7.24 million or $0.13 per common share during the six months ended June 30, 2007 (the "First Half of 2007"). Product sales of our laser base stations and treatment kits during the Second Quarter of 2008 amounted to $0.26 million with a gross margin of $0.18 million (69.8%) compared to product sales of $0.51 million and a gross margin of $0.23 million (45.6%) during the Second Quarter of 2007. Product sales of our laser base stations and treatment kits during the First Half of 2008 amounted
'/>"/>

SOURCE Ondine Biopharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Ondine to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
8. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/28/2014)... NY (PRWEB) August 28, 2014 Whitehouse ... its long term partnership with PTI Inspection Systems ... clients with state of the art leak testing method ... the art instruments currently available. As part of this ... High Voltage Leak Detection Instrument developed and ...
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
(Date:8/27/2014)... August 27, 2014 In 2013, ... Lawrence Livermore National Security LLC (LLNS), ... and deliver a state-of-the-art laser system for the ... Beamlines), under construction in the Czech Republic. , ... laser system, called the " High repetition-rate Advanced ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... young Swiss biotech,enterprise AMVAC AG has gained reinforcement ... renowned vaccine specialists. Prof. Klein, who was,formerly Vice ... will immediately assume directorship of the scientific sector ... has,access to an outstanding network across one of ...
... ... Zingo, ... Inc. (Nasdaq: ANSV ) and Sagent,Pharmaceuticals, Inc., today announced an ... hydrochloride,monohydrate) powder intradermal injection product and will manage U.S.,distribution. Zingo, a ...
... Solstice Neurosciences, Inc.,("Solstice") announced the appointment of Dennis ... will serve as Executive Chairman replacing James,Thomas, who ... since Solstice,was founded in July 2004. Mr. ... to Solstice that will be invaluable in providing ...
Cached Biology Technology:Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC 2Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals 2Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals 3Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals 4Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc. 2
(Date:8/27/2014)... the Volunteer Wildfire Services of South Africa as "Cape ... residents in certain parts of the province on Monday ... high veld fire danger rating is expected in the ... Kei and Mnquma area. Strong winds often occurred ... bring lightning strikes and subsequent fire and the wind ...
(Date:8/27/2014)... available in German . ... most common inherited disease affecting the peripheral nervous system. ... Planck Institute of Experimental Medicine and University Medical Centre ... is impaired in rats with the disease. These cells ... as myelin, which facilitates the rapid transfer of electrical ...
(Date:8/27/2014)... belief that a deficiency in serotonin a chemical ... in depression. In the journal ACS Chemical Neuroscience ... make serotonin in their brains (and thus should have ... symptoms. , Donald Kuhn and colleagues at the ... University School of Medicine note that depression poses a ...
Breaking Biology News(10 mins):Potential therapy for incurable Charcot-Marie-Tooth disease 2New study throws into question long-held belief about depression 2
... to treat amyotrophic lateral sclerosis (ALS) suggest that the ... disease, one of the most common neuromuscular disorders in ... Research Institute at Nationwide Children,s Hospital and the Ludwig ... a survival increase of up to 39 percent in ...
... among the nation,s most innovative users of business technology. ... announced and can be viewed at http://www.informationweek.com/500 . ... most innovative users of information technology and tracks the ... the best-known organizations in the country. Past overall winners ...
... were announced today in Milan by the Chairman of ... the President of the Balzan "Prize" Foundation, Ambassador Bruno ... The profiles of the winners and the citations (the ... be held in Bern on November 15) were presented ...
Cached Biology News:Therapy slows onset and progression of Lou Gehrig's disease, study finds 2Therapy slows onset and progression of Lou Gehrig's disease, study finds 3Therapy slows onset and progression of Lou Gehrig's disease, study finds 42013 Balzan prizewinners announced today in press conference in Milan 22013 Balzan prizewinners announced today in press conference in Milan 3
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... Exiqon's miRCURY LNA technology enables sensitive ... Northern blotting. miRCURY LNA Detection probes have ... specific and sensitive detection of miRNAs. Due ... miRCURY LNA probes less than 1/10 the ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length Vitronectin protein (Mouse). Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: